Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 51, 2011, Pages 20509-20513

  Powdrill, Megan H ^a   Tchesnokov, Egor P ^a   Kozak, Robert A ^a   Russell, Rodney S ^b   Martin, Ross ^c   Svarovskaia, Evguenia S ^c   Mo, Hongmei ^c   Kouyos, Roger D ^d   Götte, Matthias ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^c GILEAD SCIENCES   (United States)

^d PRINCETON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; NONSTRUCTURAL PROTEIN 5B; NUCLEOTIDE; RNA DIRECTED RNA POLYMERASE; VIRUS RNA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME KINETICS; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VIVO STUDY; PRIORITY JOURNAL; VIRUS GENOME; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BASE SEQUENCE; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; GENETIC VARIATION; GENOTYPE; HEPACIVIRUS; KINETICS; MODELS, GENETIC; MODELS, THEORETICAL; MOLECULAR SEQUENCE DATA; MUTATION; SEQUENCE ANALYSIS, DNA; STOCHASTIC PROCESSES; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 84855509792     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1105797108     Document Type: Article

References (31)

1. Global Burden of Hepatitis C Working Group (2004) Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 44:20-29.
2. Kanwal F, et al. (2011) Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 140:1182-1188.e1.
3. FriedMW, et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982.
4. Pawlotsky JM (2004) Treating hepatitis C in "difficult-to- treat" patients. N Engl J Med 351:422-423.
5. Bacon BR, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364:1207-1217.
6. Marcellin P, et al. (2011) Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 140:459-468.e1.
7. Pawlotsky J-M (2011) Treatment failure and resistance with direct acting antiviral drugs against hepatitis C virus. Hepatology 53:1742-1751.
8. Martell M, et al. (1992) Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: Quasispecies nature of HCV genome distribution. J Virol 66:3225-3229.
9. Pawlotsky JM (2011) Treatment failure and resistancewith direct-acting antiviral drugs against hepatitis C virus. Hepatology 53:1742-1751.
10. Gao M, et al. (2010) Chemical genetics strategy identifies an HCV NS5A inhibitorwith a potent clinical effect. Nature 465:96-100.
11. Migliaccio G, et al. (2003) Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem 278:49164-49170.
12. Le Pogam S, et al. (2010) No evidence of drug resistance or baseline S282T resistance mutation among GT1 and GT4 HCV infected patients on nucleoside polymerase inhibitor RG7128 and Peg-IFN/RBV combination treatment for up to 12 weeks: Interim analysis from the PROPEL study. Hepatology 52:701A-702A.
13. Coelmont L, et al. (2009) Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) Inhibitors. Antimicrob Agents Chemother 53:967-976.
14. Puyang X, et al. (2010) Mechanism of resistance of HCV replicons to structurally distinct cyclophilin inhibitors. Antimicrob Agents Chemother 54:1981-1987.
15. Zhong W, Uss AS, Ferrari E, Lau JY, Hong Z (2000) De novo initiation of RNA synthesis by hepatitis C virus nonstructural protein 5B polymerase. J Virol 74:2017-2022. (Pubitemid 30434061)
16. Dutartre H, Boretto J, Guillemot JC, Canard B (2005) A relaxed discrimination of 2′-O-methyl-GTP relative to GTP between de novo and elongative RNA synthesis by the hepatitis C RNA-dependent RNA polymerase NS5B. J Biol Chem 280:6359-6368. (Pubitemid 40341182)
17. Jin Z, Deval J, Johnson KA, Swinney DC (2011) Characterization of the elongation complex of dengue virus RNA polymerase: Assembly, kinetics of nucleotide incorporation, and fidelity. J Biol Chem 286:2067-2077.
18. Castro C, Arnold JJ, Cameron CE (2005) Incorporation fidelity of the viral RNA-dependent RNA polymerase: A kinetic, thermodynamic and structural perspective. Virus Res 107:141-149. (Pubitemid 40093087)
19. Zinnen S, Hsieh JC, Modrich P (1994) Misincorporation and mispaired primer extension by human immunodeficiency virus reverse transcriptase. J Biol Chem 269:24195-24202. (Pubitemid 24300960)
20. Drake JW (1993) Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci USA 90:4171-4175.
21. Duffy S, Shackelton LA, Holmes EC (2008) Rates of evolutionary change in viruses: Patterns and determinants. Nat Rev Genet 9:267-276. (Pubitemid 351399833)
22. Mansky LM, Temin HM (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69:5087-5094.
23. Arezi B, Hogrefe HH (2007) Escherichia coli DNA polymerase III ε subunit increases Moloney murine leukemia virus reverse transcriptase fidelity and accuracy of RT-PCR procedures. Anal Biochem 360:84-91. (Pubitemid 44894344)
24. Kato N, et al. (2005) Genetic variation and dynamics of hepatitis C virus replicons in long-term cell culture. J Gen Virol 86:645-656. (Pubitemid 40331245)
25. Fernandez J, et al. (2004) Long-term persistence of infection in chimpanzees inoculated with an infectious hepatitis C virus clone is associated with a decrease in the viral amino acid substitution rate and low levels of heterogeneity. J Virol 78:9782-9789. (Pubitemid 39187096)
26. McHutchison JG, et al. (2009) Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 360:1827-1838.
27. Rong L, Dahari H, Ribeiro RM, Perelson AS (2010) Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2:30ra32.
28. Chatel-Chaix L, Baril M, Lamarre D (2010) Hepatitis C virus NS3/4A protease inhibitors: A light at the end of the tunnel. Viruses 2:1752-1765.
29. Le Pogam S, et al. (2006) In vitro selected Con1 subgenomic replicons resistant to 2′-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 351:349-359. (Pubitemid 44108072)
30. Ali S, et al. (2008) Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob Agents Chemother 52:4356-4369.
31. Robinson M, et al. (2010) Novel hepatitis C virus reporter replicon cell lines enable efficient antiviral screening against genotype 1a. Antimicrob Agents Chemother 54:3099-3106.